sGC activator, cinaciguat, alleviate chemical cystitis-induced pelvic pain in mice

Ikeda Y1, Zabbarova I1, Tyagi P1, Yan X1, Drake M2, Fry C3, Birder L1, Kanai A1

Research Type

Pure and Applied Science / Translational

Abstract Category

Pelvic Pain Syndromes

Abstract 130
Science 1 - Pelvic Pain
Scientific Podium Short Oral Session 11
Thursday 18th September 2025
17:07 - 17:15
Parallel Hall 4
Animal Study Basic Science Pain, Pelvic/Perineal Pharmacology
1. University of Pittsburgh, 2. Imperial College London, 3. University of Bristol
Presenter
Links

Abstract

Hypothesis / aims of study
Long-term inflammation of the urinary bladder is associated with tissue damage and afferent nerve sensitization. In some cases, inflammation can progress to chronic pelvic pain, believed to result from sensitization of sensory nerves that co-innervate multiple tissues. An effective treatment for pelvic pain has been elusive as treating the inflammation does not always mitigate the pain responses. Previous studies have suggested nitric oxide (NO) mediated cGMP signalling can reduce sensitization of bladder sensory nerves [1], however, whether the pathway also affects referred pelvic pain responses is unclear. Therefore, we investigate the effect of a small molecule soluble guanylate cyclase (sGC) activator, on nociceptive responses in a cyclophosphamide (CYP) induced chronic bladder inflammation model.
Study design, materials and methods
Animal. Adult (8 to 12 weeks old) male and female C57Bl/6J mice were purchased from Jackson Labs. Chemical cystitis was induced by four intraperitoneal administrations of CYP (50 mg/kg in sterile saline) over a 7-day period based on a previously reported protocol [2]. After completion of CYP treatment, mice were implanted with a subcutaneous osmotic pump to deliver cinaciguat (10 mg/kg/day) or vehicle (50% DMSO/50% PEG-400) for 14 days (figure 1A). 

Pelvic tactile sensitivity evaluation. Tactile sensitization of the pelvic region was evaluated using the MouseMet electronic Von Frey device (Topcat Metrology). Mice were placed into specialized testing cages and allowed to acclimate for a minimum of 30 minutes. The lower abdomen was probed at least five times during the session to determine the tactile threshold.

Data and statistical analysis. Data are expressed as mean ± standard error of mean. Statistical analyses were performed in GraphPad Prism 10 software. Comparison of data sets were performed using a two-way ANOVA followed by Tukey’s multiple comparison post-hoc test where the null hypothesis was rejected at p<0.05.
Results
The tactile threshold of the pelvic region was significantly decreased at day 7 following CYP administration. Subsequent treatment with cinaciguat increased the mechanosensitive threshold at 14 days following cinaciguat treatment versus vehicle treated mice (figure 1B).
Interpretation of results
Cinaciguat treatment ameliorated pelvic nociception caused by chronic CYP induced bladder inflammation in both male and female mice. Based on the known actions of cinaciguat, it is hypothesized that the mode of action involves cinaciguat mediated increases in cGMP/protein kinas G signalling in sensitized afferent nerves.
Concluding message
Treatments for bladder centric pelvic pain has been limited both in number and efficacy. The NO-cGMP signalling pathway may be a new target for painful bladder syndrome/interstitial cystitis treatments.
Figure 1 Figure 1. A) Timeline of treatment protocol. B) Bar chart of pelvic tactile responses from mice before CYP, at completion of CYP administration and CYP followed with14 days of cinaciguat or vehicle treatment
References
  1. Aizawa et al. Effects of nitric oxide on primary bladder afferent activities of the rat with and without intravesical acrolein treatment, European Urology, 59(2)264-71, 2011.
  2. Golubeva et al. The mouse cyclophosphamide model of bladder pain syndrome: tissue characterization, immune profiling, and relationship to metabotropic glutamate receptors, Physiological Reports, 2(3):e00260, 2014
Disclosures
Funding National Institutes of Health Clinical Trial No Subjects Animal Species mouse Ethics Committee University of Pittsburgh Institutional Animal Care and Use Committee
02/07/2025 22:02:04